This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Gets FDA Nod for Migraine Nasal Spray Zavzpret
by Zacks Equity Research
Zavzpret (zavegepant) is now part of Pfizer's (PFE) migraine drugs portfolio with the 2022 acquisition of Biohaven. Zavzpret provides migraine patients access to a fast-acting pain-relief option.
BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
BioNTech's (BNTX) fourth-quarter COVID-19 vaccine sales are likely to have declined with the pandemic largely in control. Updates on the company's booster dose authorization status and pipeline will be in focus.
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DHS
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $40.12, moving -0.55% from the previous trading session.
Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day.
Lilly's (LLY) Verzenio Gets FDA Nod for Expanded Breast Cancer
by Zacks Equity Research
Eli Lilly (LLY) announces FDA approval of label expansion of Verzenio (abemaciclib), in combination with endocrine therapy, for treating HR+, HER2-, node-positive and high-risk early breast cancer.
Pfizer (PFE) or GSK: Who Will Get the First FDA Nod for RSV Jab?
by Zacks Equity Research
An FDA advisory committee recommended approving Pfizer's (PFE) and GSK's respective RSV vaccines for older adults. Currently, there are no RSV vaccines anywhere in the world.
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Why Is Pfizer (PFE) Down 8.6% Since Last Earnings Report?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News for Feb 28, 2023
by Zacks Equity Research
Companies in The News Are: UNP, TSLA, SGEN, PFE, NFLX
Durable Goods Orders Come in Nearly at a Three-Year Low
by Zacks Equity Research
Durable Goods Orders Come in Nearly at a Three-Year Low.
Durables Goods Sink -4.5%, but Higher on Business Spending
by Mark Vickery
These Durable Goods figures are preliminary, and subject to future revisions.
Seagen (SGEN) Likely to be Acquired by Pfizer Claims WSJ
by Zacks Equity Research
Seagen (SGEN) may be acquired by the large-cap pharma company Pfizer at a valuation of more than $30 billion, according to a Wall Street Journal article. Seagen's stock is up 17% in pre-market hours in response to the news.
Pharma Stock Roundup: FDA Updates for SNY, PFE & Others, EU Nod to AZN Cancer Combo
by Kinjel Shah
FDA approves Sanofi's (SNY) Altuviiio and grants a priority tag to Pfizer's (PFE) regulatory applications for pipeline candidates.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pharma Stock Roundup: FDA Nod to PFE Cibinqo for Adolescents, Updates From NVO, RHHBY
by Kinjel Shah
FDA approves Pfizer's (PFE) Cibinqo for adolescent patients. Roche (RHHBY) announces new positive data from phase III studies on Vabysmo for vision loss associated with retinal vein occlusion.
Pfizer (PFE) Eczema Drug Cibinqo Gets FDA Nod for Adolescents
by Zacks Equity Research
The FDA approval for Pfizer's (PFE) Cibinqo to treat moderate-to-severe atopic dermatitis in adolescents was based on data from the phase III study, JADE TEEN.
Zacks Market Edge Highlights: Pfizer, Exxon Mobil, Citigroup, Enterprise Products Partners and Intel
by Zacks Equity Research
Pfizer, Exxon Mobil, Citigroup, Enterprise Products Partners and Intel have been highlighted in this Market Edge article.
How to Build a Lottery Winning Stock Portfolio
by Tracey Ryniec
Didn't win the Powerball? Here's how to bet on yourself instead.
A Look at Pharma ETFs Post Q4 Earnings
by Sweta Killa
Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.
Deciphera's (DCPH) Q4 Earnings Miss, Qinlock Drives Revenues
by Zacks Equity Research
Deciphera (DCPH) reports a wider-than-expected loss per share for the fourth quarter of 2022, while revenues driven by Qinlock sales, beat estimates.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pharma Stock Roundup: MRK, LLY, PFE Q4 Results, J&J's Loss in Talc Lawsuits
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Eli Lilly (LLY) and others report fourth-quarter results. An appeals court dismisses J&J's (JNJ) bankruptcy filing related to its talc lawsuits.